Saflutan 15 micrograms/ml eye drops, solution
*Company:
Santen UK LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 27 June 2023
File name
spc-saflutan 15 micrograms_ml eye drops, solution APPR 20230623.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
3. PHARMACEUTICAL form
Eye drops, solution (eye drops).
A clear, colourless solution, practically free from visible particles with a pH between 5.5 and 6.7, and an osmolality of 260 - 31000 mOsmol/kg.
.
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 15th February 2019
Date of last renewal: 21st February 2023
10. DATE OF REVISION OF THE TEXT
03 February 2022 June 2023
Updated on 19 January 2023
File name
spc-taflotan-pfmd-en-ie-APPR 20220203.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 03 August 2022
File name
pil-saflutan-pfmd-en-UK_ie-APPR 20220721.pdf
Reasons for updating
- Change to section 6 - date of revision
- Change to name of medicinal product
Free text change information supplied by the pharmaceutical company
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
TAFLOTAN sine: Germany
Taflotan sine: Denmark, Finland, Iceland, Norway, Sweden
Taflotan: Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Greece, Hungary, Iceland, Latvia, Lithuania, Norway, Portugal, Slovak Republic, Spain, Sweden
Taflotan Multi: Poland
Saflutan: Austria, Belgium, Croatia, Ireland, Luxembourg, The Netherlands, Romania, Slovenia, United Kingdom (Northern Ireland)
Safluround: Italy
This leaflet was last revised in 07/202212/2021
Updated on 08 February 2022
File name
pil-taflotan-pfmd-en-ie-APPR 20220203.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
5. How to store Saflutan
...
You must throw away the bottle 3 months after you first opened it, to prevent infections, and use a new bottle. The bottle with 3 ml fill volume is intended for 1 month in-use period, 5 ml fill volume bottle for 2 months and 7 ml fill volume bottle for 3 months.28 days
....
6. Contents of the pack and other information
....
What Saflutan looks like and contents of the pack
Saflutan is a clear, colourless liquid (solution), practically free from visible particles. It is supplied in a pack containing either 1 or 3transparent plastic bottle with 3 ml, 5 ml or 7 ml, or 3 transparent plastic bottles with 3 ml solution each. The plastic bottles are closed with caps. Not all pack sizes may be marketed.s
....
This medicinal product is authorised in the Member States of the European Economic area and in the United Kingdom (Northern Ireland) under the following names:EEA
...
Austria, Belgium, Croatia, Ireland, Luxembourg, The Netherlands, Romania, Slovenia, United Kingdom (Northern Ireland)
Saflutan
....
This leaflet was last revised in 12/202108
Updated on 08 February 2022
File name
spc-taflotan-pfmd-en-ie-APPR 20220203.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
6.3 Shelf life
3 years.
After first opening the bottle: 3 months.28 days
6.4 Special precautions for storage
Store in a refrigerator (2°C -8°C). Do not freeze.
After opening: Store below 25°C.
Store in the original carton in order to protect from light.
6.5 Nature and contents of container
Transparent low-density polyethylene (LDPE) bottles with white Aptar OSD (polyethylene, polypropylene, cyclic olefin copolymer) with blue polyethylene cap. Each bottle has a fill volume of 3 ml, 5 ml or 7 ml.
The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml (each intended for 1 month patient’s in use period), 1 bottle of 5 ml (for 2 months) or 1 bottle of 7 ml (for 3 months).
Not all pack sizes may be marketed.
10. DATE OF REVISION OF THE TEXT
03 February 202217 September 2021
Updated on 21 September 2021
File name
pil-saflutan-pfmd-en-ie-APPR 20210917.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Section 3
When you start a new bottle:
Do not use the bottle if the pouch is brokenplastic ring around the bottle neck is missing or broken. or if the Write down the date you opened the bottle in the space reserved for the date on the outer carton.Open the pouch along the dashed line.
Section 6
What Saflutan contains
- The active substance is tafluprost. 1 ml of solution contains 15 micrograms of tafluprost. One drop contains about 0.45 micrograms of tafluprost.
- The other ingredients are glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, polysorbate 80, and water for injections. Hydrochloric acid and/or sodium hydroxide are added to adjust the pH.
What Saflutan looks like and contents of the pack
Tradename] Saflutan is a clear, colourless liquid (solution), practically free from visible particles. It is supplied in a pack containing either 1 or 3 transparent plastic bottles with 3 ml solution each. The plastic bottles are closed with caps. [Not all pack sizes may be marketed.Each bottle is packed in a pouch.
This leaflet was last revised in 09/202 08/20210
Updated on 21 September 2021
File name
spc-saflutan-pfmd-en-ie-APPR 20210917.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 6.5
Transparent low-density polyethylene (LDPE) bottles with white Aptar OSD (polyethylene, polypropylene, cyclic olefin copolymer) with blue polyethylene cap. Each bottle has a fill volume of 3 ml. packed in a PET coated aluminium/polyethylene foil pouch
The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml each. packed in pouch
Not all pack sizes may be marketed.
Section 10
17 September 202117 December 2020
Updated on 18 December 2020
File name
spc-saflutan-pfmd-en-ie-APPR 20201217.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml of solution contains 15 micrograms of tafluprost
One drop contains about 0.45 micrograms of tafluprost.
Excipient with known effect: One ml of eye drops solution contains 1.2 mg phosphates and one drop contains approximately 0.04 mg phosphates.
For the full list of excipients, see section 6.1.
10 DATE OF REVISION OF THE TEXT
January 2020 17/12/2020
Updated on 18 December 2020
File name
pl-saflutan-pfmd-en-ie-APPR 20201217.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
ADDED to section 2:
Saflutan contains phosphates
This medicine contains approximately 0.04 mg phosphates in each drop which is equivalent to 1.2 mg/ml. If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.
DELETED from section 4
In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.
This leaflet was last revised in 03/2020 09/2020
Updated on 24 March 2020
File name
pil-saflutan-pfmd-en-uk-ie 20200316.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Section 4
...
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom: Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie; e-mail: medsafety@hpra.ieIreland: HPRA Pharmacovigilance, Website: www.hpra.ie..
.................
Section 6
.......
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Santen Oy
Niittyhaankatu 20
33720 Tampere
FINLAND
Vianex S.A
Tatoiou Street
14671Nea Erithrea
Greece
Manufacturer
Santen Oy
Niittyhaankatu 20
33720
Kelloportinkatu 1
33100 Tampere
FINLAND
This leaflet was last revised in 03/202012/2019
Updated on 13 January 2020
File name
pil-taflotan-pfmd-en-ie-APPR-20200103.pdf
Reasons for updating
- XPIL Updated
Free text change information supplied by the pharmaceutical company
XPIL updated (revision date and documnet refernce number) to align with recently published PIL
Updated on 10 January 2020
File name
pil-taflotan-pfmd-en-ie-APPR-20200103.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 5 - how to store or dispose
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Section 3
…
- Put the cap back on and close the bottle tightly.
There will be a residual volume of approximately 1 ml, which cannot be dosed. Do not try to empty the bottle. after the amount required for 28 days is used
…
Section 5
…
Store in the refrigerator (2°C – 8°C). Do not freeze.
After opening, store below 25°C.
Store in the original carton in order to protect from light.
…
Section 6
Add manufacturer:
Vianex S.A
Tatoiou Street
14671Nea Erithrea
Greece
Change date of revision from 8/19 to 12/19
Updated on 10 January 2020
File name
spc-taflotan-pfmd-en-ie-APPR-20200103.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
section 4.2
....
There will be a residual volume of approximately 1 ml, which cannot be dosed. The patient should not try to empty the bottle. after the amount required for 28 days is used.
......
section 6.4
Store in a refrigerator (2°C -8°C). Do not freeze.
After opening: Store below 25°C.
Store in the original carton in order to protect from light.
section 6.5
Transparent low-density polyethylene (LDPE) bottles with white Aptar OSD (polyethylene, polypropylene, cyclic olefin copolymer) with blue polyethylene cap packed in a PET coated aluminium/polyethylene foil pouch. Each bottle has a fill volume of 3 ml.thermoplastic elastomer
The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml each packed in pouch.
Not all pack sizes may be marketed.
section 10
15.2.2019 January 2020
Updated on 17 September 2019
File name
pil-taflotan-pfmd-en-ie-APPR-20190802.pdf
Reasons for updating
- New PIL for medicines.ie
Updated on 17 September 2019
File name
pil-taflotan-pfmd-en-ie-APPR-20190802.pdf
Reasons for updating
- New PIL for medicines.ie
Updated on 16 September 2019
File name
pil-taflotan-pfmd-en-ie-APPR-20190802.pdf
Reasons for updating
- New PIL for medicines.ie
Free text change information supplied by the pharmaceutical company
new leaflet for new product
Updated on 16 September 2019
File name
pil-taflotan-pfmd-en-ie-APPR-20190802.pdf
Reasons for updating
- New PIL for medicines.ie
Free text change information supplied by the pharmaceutical company
New leaflet for new product.
Updated on 16 September 2019
File name
pil-taflotan-pfmd-en-ie-APPR-20190802.pdf
Reasons for updating
- New PIL for new product
Updated on 16 September 2019
File name
spc-taflotan-pfmd-en-ie-APPR-20190215.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)